Latent Health has raised $80 million in Series A funding to broaden the reach of its AI platform designed to help patients receive prescribed therapies faster. The round was co-led by Spark Capital and Transformation Capital, with participation from Conviction, McKesson Ventures, General Catalyst, and Y Combinator. Founded by Sriram Somasundaram and Rishabh Jain, the company develops what it calls a Clinical Reasoning Engine that interprets patient records, applies drug eligibility rules, extracts supporting evidence, and coordinates workflows across hospitals, pharmacies, payers, and patients.
The company said the system addresses one of healthcare’s most persistent bottlenecks, where treatment approvals often stall because clinical documentation and insurance requirements remain heavily manual. Latent said, “For the first time, AI makes it possible to close the distance between a therapeutic decision and a patient receiving therapy.”
The company also said more than 2 million patients have already received faster access to medications through its platform, which now works with more than 45 health system partners and 50% of the top 20 U.S. health systems, including Yale New Haven Health, Vanderbilt Health, Mount Sinai Health System, UCSF Health, and UCLA Health.
Latent said its technology has reduced denials by more than 30% and helped clinicians manage roughly twice as many patients across multiple specialties. The company said it is “building the infrastructure for the intersection of clinicians, patients, and payers,” and plans to use the new capital to deepen platform capabilities, improve reliability, expand its hospital network, and grow its workforce.
